Cardiac ArrestNCT04366297
Intravascular Access of COVID-19 Patient Under Personal Protective Equipment
A study testing Intravenous access and Intraosseous access in people with Cardiac Arrest and Emergencies, run by Lazarski University at 1 site in Poland.
Trial summary
The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiac Arrest, Emergencies
- What is being tested?
- Intravenous access and Intraosseous access
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 41 participants
- Where
- 1 sitePoland
- Study dates
- 12 Jan 2020to 25 Feb 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- paramedic
- consent voluntary participation in the study
- none experience in resuscitation with personal protective equipment
Who cannot join
- refusal to participate in the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial
The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.
- Conditions
- Cardiac Arrest, Emergencies
- Being tested
- Intravenous access, Intraosseous access
- Keywords
- intravascular access, COVID-19, personal protective equipment, medical simulation
- Medical subject headings
- Heart Arrest, Emergencies, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intravenous accessDevice
Also called IV
obtaining intravascular access using a standard intravenous cannula
Intraosseous accessDevice
Also called IO
obtaining intravascular access using a ready intravenous NIO needle set
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care (Intravenous Cannula) | Experimental | obtaining intravascular access using a ready standard intravenous cannula Receives: Device: Intravenous access |
| IO access using NIO® set | Experimental | receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®. Receives: Device: Intraosseous access |
What is being measured
The primary outcome is the main question the study is designed to answer.
successful rate of first intravascular access attempt
successful placement of intravascular device
Measured: 1 day
Secondary outcomes (6)
time to successful access
Measured: 1 day
number of attempts to successful access
number of attempts to successful access
Measured: 1 day
time to infusion
time to therapy including but not limited to time to fluids, antibiotics, and antiarrythmics
Measured: 1 day
complication rates
complication rates
Measured: 1 day
ease of use
self-reported percentage the vocal cord visualization. A 100% score is a extremely difficult procedure. A Ease of use score of 1% means that procedure is extremely easy
Measured: 1 day
Preferred intravascular access method
participants were asked which method of intravascular access they would prefer in a real-life resuscitation.
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2020
- Study start12 Jan 2020
- Primary completion25 Feb 2020
- Study completion25 Feb 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiac ArrestStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lazarski University
- Sponsor type
- University, hospital or other
- Collaborators
- Poznan University of Medical Sciences, Medical University of Bialystok, Wroclaw Medical University
- Responsible party
- Principal investigator, Łukasz Szarpak, Lazarski University
- Investigators
- Jacek Smereka, PhD, Principal investigator, Wroclaw Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04366297
- Sponsor's protocol ID
- IO_PPE_MS_1
- Status last verified
- Apr 2020
- First submitted
- 23 Apr 2020
- Last updated
- 28 Apr 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: the investigators will add data into manuscript
Publications
Smereka J, Szarpak L, Filipiak KJ, Jaguszewski M, Ladny JR. Which intravascular access should we use in patients with suspected/confirmed COVID-19? Resuscitation. 2020 Jun;151:8-9. doi: 10.1016/j.resuscitation.2020.04.014. Epub 2020 Apr 15. No abstract available.
PubMed 32304800
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial
- ClinicalTrials.gov ID
- NCT04366297
- Acronym / sponsor ID
- IO_PPE_MS_1
- Conditions
- Cardiac Arrest, Emergencies
- Keywords
- intravascular access, COVID-19, personal protective equipment, medical simulation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- Lazarski UniversityUniversity, hospital or other
- Collaborators
- Poznan University of Medical Sciences, Medical University of Bialystok, Wroclaw Medical University
- Study start
- 12 Jan 2020 (actual)
- Primary completion
- 25 Feb 2020 (actual)
- Study completion
- 25 Feb 2020 (actual)
- First posted
- 28 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard of Care (Intravenous Cannula) | Experimental | Device: Intravenous accessobtaining intravascular access using a ready standard intravenous cannula |
| IO access using NIO® set | Experimental | Device: Intraosseous accessreceive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- paramedic
- consent voluntary participation in the study
- none experience in resuscitation with personal protective equipment
Key exclusion criteria (1 listed)
- refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intravenous accessAlso: IVobtaining intravascular access using a standard intravenous cannula | Device | Standard of Care (Intravenous Cannula) |
| Intraosseous accessAlso: IOobtaining intravascular access using a ready intravenous NIO needle set | Device | IO access using NIO® set |
Primary outcome
successful rate of first intravascular access attempt
Time frame: 1 day
successful placement of intravascular device
6 secondary outcomes
time to successful access
Time frame: 1 day
number of attempts to successful access
Time frame: 1 day
time to infusion
Time frame: 1 day
complication rates
Time frame: 1 day
ease of use
Time frame: 1 day
Preferred intravascular access method
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2020.
- Background: PubMed 32304800Smereka J, Szarpak L, Filipiak KJ, Jaguszewski M, Ladny JR. Which intravascular access should we use in patients with suspected/confirmed COVID-19? Resuscitation. 2020 Jun;151:8-9. doi: 10.1016/j.resuscitation.2020.04.014. Epub 2020 Apr 15. No abstract available.
- Individual participant dataSharing planned: Undecided. the investigators will add data into manuscript
Related trials for Cardiac Arrest
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingPhase 3
The Danish Out-of-Hospital Cardiac Arrest Study
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
RecruitingObservational study
Evaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm
Cardiac Arrest (CA), Cardiogenic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jacek Smereka, PhD principal investigator
Wroclaw Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intravenous access and Intraosseous access in people with Cardiac Arrest and Emergencies, run by Lazarski University at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
successful rate of first intravascular access attempt (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04366297, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2020.